ImmuCell Corp (ICCC) shareholders
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3021% above fair value
$10.75+0.53 (+5.19%)
Close on Nov 13, 2026Market cap $97.63MP/E 53.8Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
14.7%
1M of 9M shares
Institutional holders
31
7 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
8 buys · 0 sales
Net bought $171.69K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ejnar A. Knudsen III | 832,790 | 9.21% | 13D (active) amendment | Nov 19, 2025 |
| Srk Fund I, LP Joint filing with SRK Capital, LLC (6.40%), Sean Kirkwood (6.40%) | 502,258 | 6.40% | 13D (active) amendment | Sep 17, 2024 |
| SRK Capital, LLC Joint filing with Srk Fund I, LP (5.00%), Sean Kirkwood (5.00%) | 391,322 | 5.00% | 13D (active) | May 22, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ICCC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 268,130 | 2.95% | $2.69M | +7,803 | 0.00% |
| Morgan Stanley | 233,910 | 2.58% | $2.35M | +12,194 | 0.00% |
| Renaissance Technologies LLC | 171,089 | 1.88% | $1.72M | +19,300 | 0.00% |
| Cresset Asset Management, LLC | 135,267 | 1.49% | $1.36M | – | 0.00% |
| Geode Capital Management, LLC | 72,270 | 0.80% | $726.49K | +6,505 | 0.00% |
| Dimensional Fund Advisors LP | 58,452 | 0.64% | $587.44K | +2,422 | 0.00% |
| Bleichroeder LP | 50,000 | 0.55% | $502.50K | −51,594 | 0.09% |
| Steadtrust LLC | 45,370 | 0.50% | $455.97K | −9,000 | 0.23% |
| Mesirow Financial Investment Management, Inc. | 42,481 | 0.47% | $426.93K | – | 0.01% |
| Citadel Advisors LLC | 40,503 | 0.45% | $407.06K | +4,807 | 0.00% |
| Vanguard Fiduciary Trust Co | 37,766 | 0.42% | $379.55K | −4,903 | 0.00% |
| Strategic Financial Services, Inc, | 37,000 | 0.41% | $371.85K | – | 235348.10% |
| HighTower Advisors, LLC | 24,354 | 0.27% | $244.76K | – | 0.00% |
| BlackRock, Inc. | 22,860 | 0.25% | $229.74K | +4,674 | 0.00% |
| Jane Street Group, LLC | 15,751 | 0.17% | $158.30K | New | 0.00% |
| Quadrature Capital Ltd | 15,415 | 0.17% | $154.92K | New | 0.00% |
| Northern Trust Corp | 14,721 | 0.16% | $147.95K | −26,897 | 0.00% |
| Mercer Global Advisors Inc /Adv | 12,000 | 0.13% | $120.60K | New | 0.00% |
| Bailard, Inc. | 10,102 | 0.11% | $101.53K | – | 0.00% |
| Shufro Rose & Co LLC | 10,000 | 0.11% | $100.50K | −25,000 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 31 | 1M | 14.7% | 7 / 7 | 7 / 3 | 0M | 0M |
| Q1 2026 | 27 | 1M | 15.5% | 5 / 7 | 4 / 3 | 0M | 0M |
| Q4 2025 | 26 | 1M | 14.1% | 2 / 9 | 6 / 3 | 0M | 0M |
| Q3 2025 | 27 | 1M | 14.1% | 4 / 4 | 7 / 2 | 0M | 0M |
| Q2 2025 | 25 | 1M | 14.5% | 1 / 9 | 2 / 3 | 0M | 0M |
| Q1 2025 | 27 | 1M | 13.3% | 0 / 7 | 7 / 0 | 0M | 0M |
| Q4 2024 | 27 | 1M | 13.3% | 5 / 5 | 8 / 0 | 0M | 0M |
| Q3 2024 | 22 | 1M | 12.7% | 1 / 7 | 4 / 6 | 0M | 0M |
| Q2 2024 | 28 | 1M | 12.6% | 3 / 7 | 9 / 0 | 0M | 0M |
| Q1 2024 | 25 | 1M | 12.6% | 0 / 7 | 7 / 3 | 0M | 0M |
| Q4 2023 | 28 | 1M | 12.4% | 2 / 10 | 4 / 4 | 0M | 0M |
| Q3 2023 | 30 | 1M | 11.4% | 3 / 6 | 10 / 4 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
24 funds held ICCC in Q2 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ICCC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 181,077 | 1.99% | $1.82M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 78,987 | 0.87% | $793.82K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 27,128 | 0.30% | $277.79K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 21,098 | 0.23% | $212.03K | 0.01% | Jun 30, 2026 |
| U.S. Core Equity 2 Portfolio | 18,384 | 0.20% | $206.08K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 13,563 | 0.15% | $138.89K | 0.00% | May 31, 2026 |
| Nationwide Bailard Small Cap Value Fund | 10,102 | 0.11% | $113.24K | 0.09% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 9,429 | 0.10% | $96.55K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 5,165 | 0.06% | $51.91K | 0.00% | Jun 30, 2026 |
| U.S. Targeted Value Portfolio | 4,747 | 0.05% | $53.21K | 0.00% | Jul 31, 2026 |
| U.S. Vector Equity Portfolio | 2,993 | 0.03% | $33.55K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 2,901 | 0.03% | $29.16K | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Targeted Value ETF | 2,781 | 0.03% | $31.18K | 0.00% | Jul 31, 2026 |
| U.S. Sustainability Core 1 Portfolio | 2,176 | 0.02% | $24.39K | 0.00% | Jul 31, 2026 |
| U.S. Social Core Equity 2 Portfolio | 2,105 | 0.02% | $23.60K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Boekhorst Paul Francis Olivier te | President and CEO, Director | 17,785 | 0.20% | Jun 22, 2026 |
| Bobbi Jo Brockmann | VP of Sales and Marketing, Director | 9,576 | 0.11% | Apr 14, 2026 |
| Timothy C. Fiori | Chief Financial Officer, Director | – | – | Jan 29, 2026 |
| Anthony DiMarco | Director | – | – | Apr 23, 2026 |
| Gilles Guillemette | Director | – | – | Apr 23, 2026 |
| Gloria F. Basse | Director | 3,530 | 0.04% | Apr 16, 2026 |
| David Scott Tomsche | Director | 131,387 | 1.45% | Apr 16, 2026 |
| Paul R. Wainman | Director | 6,269 | 0.07% | Apr 16, 2026 |
| Kathy V. Turner | Director | – | – | Apr 16, 2026 |
| Bryan K. Gathagan | Director | 1,000 | 0.01% | Apr 14, 2026 |
| Steven T. Rosgen | Director | – | – | Apr 14, 2026 |
| Michael F. Brigham | Director | 229,752 | 2.53% | Mar 24, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Boekhorst Paul Francis Olivier te President and CEO, Director | Jun 18, 2026 | Buy | +8,000 | $9.50 | $76.00K | 17,785 |
| Michael F. Brigham Director | Mar 20, 2026 | Option exercise | +25,000 | $5.84 | $146.00K | 229,752 |
| Michael F. Brigham Director | Mar 20, 2026 | Tax withholding | −24,052 | $6.07 | $146.00K | 205,700 |
| Boekhorst Paul Francis Olivier te President and CEO, Director | Dec 4, 2025 | Buy | +2,432 | $5.50 | $13.38K | 9,738 |
| Boekhorst Paul Francis Olivier te President and CEO, Director | Dec 3, 2025 | Buy | +3,598 | $5.05 | $18.17K | 7,306 |
| Boekhorst Paul Francis Olivier te President and CEO, Director | Dec 3, 2025 | Buy | +3,521 | $5.04 | $17.75K | 9,785 |
| Boekhorst Paul Francis Olivier te President and CEO, Director | Dec 3, 2025 | Buy | +2,556 | $5.00 | $12.78K | 6,264 |
| Boekhorst Paul Francis Olivier te President and CEO, Director | Dec 2, 2025 | Buy | +3,708 | $4.87 | $18.06K | 3,708 |
| David Scott Tomsche Director | Nov 25, 2025 | Buy | +1,633 | $4.77 | $7.79K | 4,740 |
| David Scott Tomsche Director | Nov 25, 2025 | Buy | +1,633 | $4.76 | $7.77K | 52,720 |
| Bryan K. Gathagan Director | Jun 12, 2025 | Buy | +1,000 | $6.32 | $6.32K | 1,000 |
| Gloria F. Basse Director | Jun 11, 2025 | Option exercise | +3,530 | $4.81 | $16.98K | 3,530 |
| David Scott Tomsche Director | Aug 28, 2024 | Returned to company | +2,186 | $3.55 | $7.76K | 131,797 |
| David Scott Tomsche Director | Aug 23, 2024 | Returned to company | +6,005 | $3.55 | $21.32K | 129,611 |
| David Scott Tomsche Director | Aug 22, 2024 | Returned to company | +10,000 | $3.55 | $35.50K | 123,606 |
| David Scott Tomsche Director | Aug 19, 2024 | Returned to company | +3,172 | $3.67 | $11.64K | 113,606 |
| David Scott Tomsche Director | Aug 16, 2024 | Returned to company | +4,811 | $3.72 | $17.90K | 110,434 |
| David Scott Tomsche Director | Aug 15, 2024 | Returned to company | +2,017 | $3.57 | $7.20K | 105,623 |
| David Scott Tomsche Director | Sep 6, 2023 | Returned to company | +3,100 | $4.75 | $14.73K | 103,606 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +100 | $5.44 | $544 | 100,506 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +69 | $5.53 | $382 | 100,406 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +100 | $5.53 | $553 | 100,337 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +69 | $5.53 | $382 | 100,237 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +31 | $5.53 | $171 | 100,168 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +31 | $5.53 | $171 | 100,137 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +69 | $5.53 | $382 | 100,106 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +31 | $5.53 | $171 | 100,037 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +69 | $5.53 | $382 | 100,006 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +31 | $5.53 | $171 | 99,937 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +69 | $5.53 | $382 | 99,906 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +100 | $5.53 | $553 | 99,837 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +831 | $5.47 | $4.55K | 99,737 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +309 | $5.50 | $1.70K | 98,906 |
| David Scott Tomsche Director | Mar 14, 2023 | Returned to company | +71 | $5.50 | $391 | 98,597 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +200 | $5.25 | $1.05K | 97,326 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +300 | $5.24 | $1.57K | 97,126 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +400 | $5.20 | $2.08K | 96,826 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +100 | $5.24 | $524 | 98,526 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +100 | $5.24 | $524 | 98,426 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +10 | $5.23 | $52 | 98,326 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +7 | $5.24 | $37 | 98,316 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +3 | $5.24 | $16 | 98,309 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +80 | $5.34 | $427 | 98,306 |
| David Scott Tomsche Director | Mar 13, 2023 | Returned to company | +900 | $5.37 | $4.83K | 98,226 |
| David Scott Tomsche Director | Sep 12, 2022 | Returned to company | +606 | $7.75 | $4.70K | 96,231 |
| David Scott Tomsche Director | Sep 12, 2022 | Returned to company | +195 | $7.80 | $1.52K | 96,426 |
| David Scott Tomsche Director | Sep 9, 2022 | Returned to company | +20 | $7.70 | $154 | 95,625 |
| David Scott Tomsche Director | Sep 9, 2022 | Returned to company | +33 | $7.80 | $257 | 95,605 |
| David Scott Tomsche Director | Sep 9, 2022 | Returned to company | +647 | $7.76 | $5.02K | 95,572 |
| David Scott Tomsche Director | Sep 8, 2022 | Returned to company | +1 | $7.62 | $8 | 94,925 |
| David Scott Tomsche Director | Sep 8, 2022 | Returned to company | +260 | $7.69 | $2.00K | 94,924 |
| David Scott Tomsche Director | Sep 8, 2022 | Returned to company | +5 | $7.70 | $39 | 94,664 |
| David Scott Tomsche Director | Sep 8, 2022 | Returned to company | +5 | $7.72 | $39 | 94,659 |
| David Scott Tomsche Director | Sep 8, 2022 | Returned to company | +329 | $7.71 | $2.54K | 94,654 |
| David Scott Tomsche Director | Sep 8, 2022 | Returned to company | +306 | $7.68 | $2.35K | 94,325 |
| David Scott Tomsche Director | Jun 14, 2022 | Returned to company | +200 | $8.10 | $1.62K | 93,569 |
| David Scott Tomsche Director | Jun 14, 2022 | Returned to company | +50 | $8.05 | $403 | 93,619 |
| David Scott Tomsche Director | Jun 14, 2022 | Returned to company | +400 | $8.25 | $3.30K | 94,019 |
| David Scott Tomsche Director | Jun 13, 2022 | Returned to company | +462 | $7.81 | $3.61K | 92,746 |
| David Scott Tomsche Director | Jun 13, 2022 | Returned to company | +48 | $7.82 | $375 | 92,884 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.19%
0M shares short
Days to cover
2.8
At 0M shares a day
Change since last report
-18.8%
From 0M shares
Short volume, 20 days
37.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ImmuCell's stock actually held short. Settlement fails (shares not delivered on time) peaked at 754 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?